1 published article · Updated continuously
20 trials tracked for prematurity: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 5 citations.
Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
L-carnitine supplementation in infants shows significant positive outcomes across multiple neurodevelopmental and physiological markers. Specifically, it is associated with significantly higher brain volumes (p<0.05) and improved neurodevelopment indices (NNNS) compared to controls (p<0.05). There was no statistically significant difference in the time required to regain birthweight between infants receiving L-carnitine and those who did not (p<0.05).
Pharmacological and nutritional interventions show varying impacts on neonatal outcomes. PCV13 administration resulted in a significantly lower occurrence of apnea (p=0.0104), though it did not significantly impact the number or duration of apneic episodes (p>0.05). Intralipid (20% intravenous emulsion) was evaluated for bilirubin management and triglyceride levels, while indomethacin was studied in relation to intraventricular hemorrhage (IVH) at 5 postnatal days.
AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
